Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML

December 30, 2021

Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.

Advertisement

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals